Cancer-related fatigue is among the most debilitating side effects experienced by individuals receiving chemotherapy. This profound and persistent exhaustion impacts both quality of life and treatment adherence. With conventional wisdom often advising rest and minimal exertion near treatment days, this investigation probes a counterintuitive angle: could a well-timed bout of aerobic exercise actually ameliorate post-chemotherapy fatigue rather than exacerbate it? The study included 12 patients aged 45 to 65 diagnosed with metastatic breast, colorectal, or prostate cancer, all undergoing chemotherapy regimens. By employing a randomized crossover design, each participant engaged in three distinct pre-treatment scenarios—seated rest, moderate continuous aerobic exercise, and high-intensity interval exercise—allowing direct comparison within subjects.

The experimental exercise protocols were meticulously tailored to ensure mechanical work parity across modalities. Moderate continuous aerobic exercise involved 30 minutes at 50% of the participant’s submaximal power, while the high-intensity interval exercise incorporated ten separate 1-minute vigorous intervals with active recovery periods. This design factored in both exercise intensity and volume, key parameters known to modulate physiological stress and recovery responses. Immediately following each pre-chemotherapy condition, participants were closely monitored for five subsequent days to assess fluctuations in fatigue, symptom burden, mood, sleep, and physical activity.

Cancer-related fatigue exhibited a diurnal pattern, with intensities rising toward the evening. Importantly, while patterns of fatigue change over time were consistent across intervention groups, the high-intensity interval exercise condition uniquely demonstrated a statistically significant reduction in perceived fatigue on Day 5 after chemotherapy administration. This delayed beneficial effect suggests that intense aerobic exercise performed before chemotherapy might activate physiological pathways conducive to fatigue attenuation in the days following treatment. Such findings underscore a potentially critical window in which pre-treatment exercise exerts systemic effects that modulate recovery trajectories.

The study also integrated Ecological Momentary Assessment methods to capture real-time symptom fluctuations, enhancing data resolution beyond standard retrospective questionnaires. Additionally, objective accelerometer-based measurements tracked sedentary behavior, light physical activity, and moderate-to-vigorous physical activity during the critical five-day post-treatment period. Interestingly, while cancer-related fatigue demonstrated meaningful variation, no significant changes were observed in physical activity levels or sedentary time across rest or exercise conditions, suggesting that pre-chemotherapy exercise influences fatigue largely independent of subsequent changes in habitual activity.

However, the investigation did note some trade-offs. Nausea severity appeared to increase transiently after high-intensity interval exercise, showing significant elevation on Day 3 post-treatment, and moderate exercise participants reported heightened nausea on Day 5. Meanwhile, mood states and sleep quality metrics remained relatively stable, indicating that these symptoms may be less sensitive to pre-treatment exercise modalities or require larger sample sizes to detect changes. Collectively, these nuanced effects highlight the complex interplay between exercise, chemotherapy toxicity, and symptom management.

Corresponding author Prof. Eléonor Riesco emphasizes the clinical importance of these findings, stressing that engaging in moderate to vigorous aerobic exercise the day before chemotherapy did not worsen fatigue, nausea, or other treatment-related symptoms—a critical reassurance for patients and clinicians alike. Furthermore, the suggestion that high-intensity interval training might mitigate cancer-related fatigue days after chemotherapy opens intriguing possibilities for incorporating tailored exercise prescriptions into standard oncological care paradigms. This proactive approach might not only improve therapeutic tolerance but also enhance patients’ overall well-being and functional capacity.

From a mechanistic standpoint, the potential benefits of pre-chemotherapy exercise could stem from several intertwined physiological processes. Exercise-induced improvements in mitochondrial function, inflammatory modulation, and enhanced muscle perfusion may collectively counteract fatigue pathways exacerbated by cytotoxic chemotherapy. High-intensity intervals, in particular, trigger significant autonomic and metabolic adaptations that could prime the body for improved resilience against treatment-induced stressors. Still, the observed transient increase in nausea after exercise underscores the need to balance intensity and symptom burden in clinical applications.

This study aligns with and reinforces international clinical oncology recommendations, such as those from the European Society for Medical Oncology and the American Society for Clinical Oncology, which advocate physical activity as a non-pharmacological intervention for managing cancer-related fatigue. Yet, the novelty here lies in the identification of the timing of exercise relative to chemotherapy sessions as a modifiable factor with clinical relevance. The researchers highlight that even modest, delayed fatigue reduction without exacerbation of symptoms is a meaningful outcome in metastatic cancer populations, where maintaining functional independence often requires nuanced therapeutic strategies.

Importantly, these findings herald a paradigm shift regarding exercise oncology by suggesting that physical activity may no longer be relegated exclusively to post-treatment rehabilitation or general health promotion but can be strategically integrated into pre-treatment routines. This opens new vistas for multidisciplinary collaboration involving oncologists, exercise physiologists, and supportive care teams to personalize exercise prescriptions and optimize patient outcomes during an otherwise challenging therapeutic phase.

While the study’s pilot design and small cohort size necessitate cautious interpretation, the rigorous crossover methodology and real-time symptom tracking provide robust preliminary data that justify larger clinical trials. Future research should aim to delineate optimal exercise intensities, durations, and timing relative to diverse chemotherapy regimens, incorporate biochemical and molecular correlates of fatigue modulation, and evaluate long-term functional and quality-of-life endpoints.

In sum, this trailblazing investigation from the University of Sherbrooke paves the way toward redefining the role of exercise within cancer care. By demonstrating that moderate-to-high-intensity aerobic exercise performed just before chemotherapy is both safe and potentially beneficial for reducing the fatigue burden in patients with advanced cancer, it offers new hope and actionable strategies to improve survivorship experiences. As the oncology community continues to embrace integrative approaches, exercise prescription tailored to treatment timing may emerge as a key pillar of supportive care, thereby enhancing resilience and empowering patients throughout their cancer journey.

Subject of Research: Effects of aerobic exercise performed the day before chemotherapy on cancer-related fatigue and active behavior in advanced cancer patients

Article Title: Effects of aerobic exercise performed the day before chemotherapy on cancer-related fatigue and active behavior in advanced cancer patients: a randomized crossover pilot study

News Publication Date: 8-Jan-2026

Web References: DOI: 10.1515/teb-2025-0037

Image Credits: Adeline Fontvieille, Hugo Parent-Roberge, Laurence Poirier, Tamàs Fülöp, Michel Pavic, and Eléonor Riesco

Keywords: Chemotherapy, cancer-related fatigue, aerobic exercise, high-intensity interval exercise, moderate continuous exercise, supportive cancer care, physical activity, metastatic cancer, fatigue management

Breast cancer remains one of the most prevalent malignancies worldwide, carrying not only physical burdens but also profound psychological and social repercussions. Fatigue and depression frequently accompany cancer treatment, often diminishing patients’ overall well-being and their ability to engage with daily activities. Traditional cognitive behavioural therapy (CBT) has been a staple in managing these psychological disturbances; however, integrating activity pacing—a structured approach to balancing activity with adequate rest—into CBT is a relatively recent innovation aimed at better aligning therapeutic strategies with patients’ lived realities.

The study involved in-depth interviews with twenty breast cancer patients aged between 24 and 62, all of whom were at various stages of cancer progression and actively receiving chemotherapy. Researchers utilized a rigorous qualitative methodology, ensuring data saturation by conducting comprehensive interviews until no novel themes emerged. Their analytical framework prioritized contextual sensitivity and methodological transparency, providing robust insights into the efficacy and reception of CBT-AP within a real-world clinical setting.

Six key thematic domains emerged from the analysis, reflecting a holistic patient experience: content of the therapy, context of delivery, implementation challenges, perceived benefits, therapeutic approach, and patient-driven recommendations. Patients articulated the integral role of each CBT-AP component, validating its relevance in addressing cancer-specific symptoms. Participants highlighted how the therapy’s content effectively acknowledged and responded to both the physical and emotional tolls of their treatment, thereby fostering a tailored approach to symptom management.

One of the most salient findings revolves around patients’ preference for different delivery modalities. While the majority favored traditional face-to-face sessions, acknowledging the value of direct interpersonal engagement with therapists, a notable subset expressed appreciation for hybrid models incorporating telephone sessions. This preference underscores the need for flexible healthcare delivery mechanisms that can accommodate varying patient circumstances and logistical constraints without compromising therapeutic efficacy.

Crucially, the participant manual accompanying the therapy was praised for its clarity and accessibility, suggesting that well-designed educational materials can empower patients to better understand and engage with therapeutic concepts. This aspect of the intervention addresses a common barrier in healthcare communication—ensuring patient comprehension—thereby enhancing adherence and fostering greater self-efficacy among patients navigating complex treatment regimens.

Beyond the acceptability of the intervention, the participants reported multifaceted benefits spanning physical, psychological, and social health dimensions. Patients described improvements not only in managing fatigue and depressive symptoms but also in reclaiming a sense of agency and social connectedness. Such outcomes highlight the therapeutic synergy achieved by integrating behavioural strategies like activity pacing with cognitive restructuring, thereby enabling patients to better regulate their energy expenditure and emotional responses.

The study also brought to light contextual factors influencing therapy outcomes. Variables such as timing relative to chemotherapy cycles, the emotional climate of the therapeutic setting, and individual differences in coping styles appeared to modulate patients’ engagement and benefit from CBT-AP. These insights underscore the importance of tailoring interventions to the nuanced realities of cancer care, suggesting that a one-size-fits-all approach may be insufficient for optimizing patient outcomes.

From an implementation science perspective, the research illuminates critical considerations regarding the feasibility of incorporating CBT-AP into routine oncology practice. Despite its demonstrated benefits, successful integration requires attention to logistical challenges, including scheduling, therapist training, and resource allocation. Patient feedback pointed towards a desire for more flexible scheduling options and enhanced therapist accessibility, factors essential for sustaining long-term engagement in behavioural interventions.

The therapeutic approach underpinning CBT-AP is characterized by its patient-centeredness—an emphasis on individualized assessment and collaborative goal-setting that respects patients’ lived experiences and preferences. This orientation appeared instrumental in fostering trust, motivation, and adherence, aligning with contemporary paradigms in psychosocial oncology that prioritize empowerment and shared decision-making.

Furthermore, participants offered valuable recommendations for refining the therapy, including enhancing digital resources, tailoring session frequency based on individual fatigue levels, and incorporating family or caregiver involvement to reinforce therapeutic gains. Such patient-informed suggestions provide actionable pathways for optimizing and scaling CBT-AP, hinting at its potential for broader applicability beyond the current study cohort.

In summary, this qualitative exploration affirms that CBT integrated with activity pacing offers a promising, patient-friendly strategy to mitigate the pervasive burden of fatigue and depression among breast cancer patients. By illuminating both the therapeutic mechanisms and contextual factors shaping patient experiences, the study enriches our understanding of how psychobehavioural interventions can be most effectively deployed in oncology settings. Its emphasis on flexibility, clarity, and patient empowerment resonates with emerging healthcare trends geared towards personalized medicine.

The research team concludes that while these findings underscore CBT-AP’s acceptability and potential benefits, further investigations are warranted to evaluate its long-term effectiveness and adaptability across diverse populations and healthcare environments. Future research directions may involve larger-scale randomized controlled trials, integration with digital health platforms, and exploration of cost-effectiveness, with the ultimate goal of embedding CBT-AP as a standard adjunct in comprehensive cancer care.

As cancer care continues to advance technologically and scientifically, this study importantly reminds us of the centrality of patient experience and subjective wellbeing. In representing the voices of those living through cancer treatment, it advocates for therapeutic models that transcend symptom management alone, fostering resilience, functional restoration, and improved quality of life.

Indeed, by bridging cognitive behavioural techniques with activity pacing, this integrative approach models how interdisciplinary collaboration within oncology and psychological sciences can produce innovative, holistic treatments. Such synergy is likely to expand the horizons of survivorship care, transforming cancer from a terminal diagnosis into a manageable chronic condition.

Ultimately, the work not only enriches academic literature but also carries profound clinical implications, reminding healthcare providers, therapists, and policy-makers alike of the vital role that tailored, flexible, and patient-informed interventions play in addressing the complex tapestry of cancer survivorship challenges.

Subject of Research:
Exploration of breast cancer patients’ subjective experiences with cognitive behavioural therapy integrated with activity pacing (CBT-AP) aimed at alleviating cancer-related fatigue and depression.

Article Title:
Patients’ experiences of cognitive behavioural therapy integrated with activity pacing: a qualitative study

Article References:
Getu, M.A., Kaba, M., Addissie, A. et al. Patients’ experiences of cognitive behavioural therapy integrated with activity pacing: a qualitative study. BMC Cancer 25, 670 (2025). https://doi.org/10.1186/s12885-025-13971-x

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-13971-x

Recognizing the critical need to address this issue, researchers at the Rogel Cancer Center, in collaboration with Arcascope, a University of Michigan spin-out, have developed a groundbreaking approach that leverages modern technology to help cancer patients manage and combat this pervasive fatigue. They have created a personalized application that meticulously tracks the user’s circadian rhythm, providing customized behavioral recommendations to help reduce daily fatigue levels. Such a personalized approach marks a significant shift from traditional generalized treatments that may not work for everyone, thus enhancing potential outcomes for patients.

The efficacy of this innovative app was elaborately documented in a recent study published in the esteemed journal, Cell Reports Medicine. The article discusses how integrating technology into patient care can yield significant benefits, especially for those who may not find relief through conventional methods, such as medications, exercise, or mindfulness practices. Professor Muneesh Tewari, a key member of the Rogel Cancer Center team, stated that the team sought to create solutions that are more easily accessible and applicable to a broader segment of the population.

Understanding that our bodies operate on an internal clock, which regulates sleep-wake cycles and numerous physiological processes over a 24-hour cycle, is fundamental to this research. Disruptions to this intricate system have been linked to exacerbations in fatigue and diminished quality of life amongst cancer patients. Interestingly, external factors, particularly light exposure, can significantly influence circadian rhythms, offering a potential pathway to mitigate fatigue through carefully timed light exposure.

In previous studies, the application of lighting treatments was often conducted in a one-size-fits-all manner, where patients were exposed to bright light at predetermined times without considering their unique circadian patterns. Caleb Mayer, a former graduate student involved in the project, emphasized the need for a more tailored approach that accommodates individual variability. Thus, the development of the Arcasync app became a pivotal step toward that goal. This innovative technology tracks users’ sleep-wake behavior by monitoring heart rate and physical activity patterns, enabling the app to generate precise recommendations for optimal exposure to light at critical times in the day.

During a comprehensive 12-week study that included 138 participants spanning various types of cancers—breast cancer, prostate cancer, and blood cancer—the researchers divided subjects into a control group and an intervention group. Each participant was asked to regularly report their fatigue levels, along with associated metrics like sleep disturbances, anxiety, depression, and overall health. The findings were compelling. Participants in the intervention group, who followed the app’s personalized recommendations, reported marked improvements in their levels of daily and weekly fatigue, signaling that individualized guidance could significantly enhance their quality of life and functionality.

Furthermore, Sung Won Choi, another prominent researcher and professor of pediatric hematology-oncology, stated that the integration of such technology into everyday life could reach far beyond the capabilities of traditional treatments, thus opening doors for enhanced patient empowerment and resilience. This innovative model not only has the potential to revolutionize how cancer-related fatigue is tackled but may also scale to benefit individuals dealing with various chronic health issues exacerbated by fatigue.

Looking forward, the research team has plans to expand their study to recruit additional participants. They are also keenly interested in understanding the extent to which individual users adhered to the app’s lighting recommendations, as this adherence may influence the outcomes experienced by patients. Olivia Walch, CEO of Arcascope, articulated the future vision for this research, stating that tackling fatigue is just the starting point. The broader ambition is to exploit the circadian clock’s mechanics to optimize the efficacy and minimize the toxicity of anticancer treatments.

By innovating the timing of medication administration and potentially synchronizing it with the body’s natural rhythms, there lies a promising future where treatments can be more effective while simultaneously alleviating side effects. The vision for future iterations of the app includes capabilities to guide patients in timing their medications or adjusting their schedules ahead of planned therapy to maximize therapeutic effectiveness.

The convergence of cancer treatment and personalized technology holds magnificent promise. As researchers continue to refine their approach and expand their understanding of circadian science, the potential to transform the landscape of cancer care becomes increasingly tangible. In this pursuit, interdisciplinary collaboration will be key, bringing together experts from medicine, engineering, mathematics, and behavioral science to create viable solutions that address the multifaceted challenges faced by cancer patients.

This innovative timing application represents a leap toward ensuring that cancer patients are not left to navigate the complexities of fatigue alone. By harnessing the power of personal data and the science of circadian rhythms, the Arcasync app embodies a forward-thinking approach to patient care, prioritizing not only the eradication of cancer but also the holistic well-being of those affected. Ultimately, this fusion of technology and biology could herald a new era of cancer management, making a significant impact on how treatment side effects are perceived and managed going forward. Advancing such research will provide invaluable insights, paving the way for more effective strategies against cancer-related fatigue and perhaps even other treatment side effects that affect the lives of countless patients globally.

Subject of Research: People
Article Title: A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue
News Publication Date: 18-Mar-2025
Web References: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00074-6
References: doi: 10.1016/j.xcrm.2025.102001
Image Credits: [To be determined]

Keywords: Cancer-related fatigue, circadian rhythms, personalized medicine, light therapy, cancer treatment management, technology in healthcare, quality of life for cancer patients.